Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACAD NASDAQ:ARWR NASDAQ:ASND NASDAQ:BBIO NASDAQ:RARE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACADACADIA Pharmaceuticals$21.82+0.4%$23.31$13.40▼$26.65$3.68B0.752.17 million shs363,338 shsARWRArrowhead Pharmaceuticals$37.43+0.2%$30.24$9.57▼$40.29$5.18B1.132.05 million shs583,898 shsASNDAscendis Pharma A/S$202.07+0.5%$199.85$118.03▼$216.45$12.47B0.41479,659 shs175,240 shsBBIOBridgeBio Pharma$55.31+2.8%$52.36$21.72▼$57.49$10.59B1.362.81 million shs368,465 shsRAREUltragenyx Pharmaceutical$33.59-0.1%$30.65$25.81▼$55.40$3.24B0.211.35 million shs385,168 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACADACADIA Pharmaceuticals+1.59%+5.38%-7.92%-6.54%+52.06%ARWRArrowhead Pharmaceuticals-0.74%-4.16%+14.92%+137.29%+87.50%ASNDAscendis Pharma A/S-0.83%-2.91%+3.62%+20.03%+57.42%BBIOBridgeBio Pharma+1.07%-2.22%+4.49%+16.22%+120.08%RAREUltragenyx Pharmaceutical+1.48%-1.00%+18.42%+23.01%-38.51%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACADACADIA Pharmaceuticals$21.82+0.4%$23.31$13.40▼$26.65$3.68B0.752.17 million shs363,338 shsARWRArrowhead Pharmaceuticals$37.43+0.2%$30.24$9.57▼$40.29$5.18B1.132.05 million shs583,898 shsASNDAscendis Pharma A/S$202.07+0.5%$199.85$118.03▼$216.45$12.47B0.41479,659 shs175,240 shsBBIOBridgeBio Pharma$55.31+2.8%$52.36$21.72▼$57.49$10.59B1.362.81 million shs368,465 shsRAREUltragenyx Pharmaceutical$33.59-0.1%$30.65$25.81▼$55.40$3.24B0.211.35 million shs385,168 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACADACADIA Pharmaceuticals+1.59%+5.38%-7.92%-6.54%+52.06%ARWRArrowhead Pharmaceuticals-0.74%-4.16%+14.92%+137.29%+87.50%ASNDAscendis Pharma A/S-0.83%-2.91%+3.62%+20.03%+57.42%BBIOBridgeBio Pharma+1.07%-2.22%+4.49%+16.22%+120.08%RAREUltragenyx Pharmaceutical+1.48%-1.00%+18.42%+23.01%-38.51%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACADACADIA Pharmaceuticals 2.65Moderate Buy$29.3334.46% UpsideARWRArrowhead Pharmaceuticals 2.78Moderate Buy$43.1415.28% UpsideASNDAscendis Pharma A/S 2.94Moderate Buy$249.8023.62% UpsideBBIOBridgeBio Pharma 2.88Moderate Buy$65.2517.98% UpsideRAREUltragenyx Pharmaceutical 2.75Moderate Buy$82.27144.91% UpsideCurrent Analyst Ratings BreakdownLatest ARWR, ACAD, ASND, BBIO, and RARE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/24/2025ARWRArrowhead PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/24/2025ASNDAscendis Pharma A/SWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/24/2025BBIOBridgeBio PharmaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/21/2025ACADACADIA PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform ➝ Buy$33.0010/21/2025BBIOBridgeBio PharmaRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$56.00 ➝ $59.0010/20/2025RAREUltragenyx PharmaceuticalWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$65.0010/17/2025ASNDAscendis Pharma A/SRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageStrong-Buy$271.0010/16/2025ASNDAscendis Pharma A/SRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy10/14/2025ACADACADIA PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)10/13/2025ASNDAscendis Pharma A/SCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$203.00 ➝ $254.0010/9/2025ASNDAscendis Pharma A/SJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$260.00 ➝ $264.00(Data available from 10/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACADACADIA Pharmaceuticals$957.80M3.84$0.72 per share30.35$4.40 per share4.96ARWRArrowhead Pharmaceuticals$572.98M9.03N/AN/A$1.54 per share24.30ASNDAscendis Pharma A/S$393.54M31.68N/AN/A($1.88) per share-107.49BBIOBridgeBio Pharma$221.90M47.65N/AN/A($7.71) per share-7.17RAREUltragenyx Pharmaceutical$560.23M5.78N/AN/A$2.76 per share12.17Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACADACADIA Pharmaceuticals$226.45M$1.3316.4028.707.3921.80%14.69%9.41%11/5/2025 (Estimated)ARWRArrowhead Pharmaceuticals-$599.49M-$1.28N/AN/AN/AN/A-40.91%-11.62%11/25/2025 (Estimated)ASNDAscendis Pharma A/S-$409.12M-$5.16N/A841.97N/A-54.94%N/A-24.31%11/13/2025 (Estimated)BBIOBridgeBio Pharma-$535.76M-$4.09N/AN/AN/A-329.25%N/A-85.69%11/11/2025 (Estimated)RAREUltragenyx Pharmaceutical-$569.18M-$5.53N/AN/AN/A-87.34%-237.48%-37.66%11/4/2025 (Estimated)Latest ARWR, ACAD, ASND, BBIO, and RARE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/13/2025Q3 2025ASNDAscendis Pharma A/S-$0.49N/AN/AN/AN/AN/A11/11/2025Q3 2025BBIOBridgeBio Pharma-$0.89N/AN/AN/A$107.71 millionN/A11/5/2025Q3 2025ACADACADIA Pharmaceuticals$0.14N/AN/AN/A$276.52 millionN/A11/4/2025Q3 2025RAREUltragenyx Pharmaceutical-$1.23N/AN/AN/A$167.42 millionN/A8/7/2025Q3 2025ARWRArrowhead Pharmaceuticals-$0.94-$1.26-$0.32-$1.26$29.01 million$27.77 million8/7/2025Q2 2025ASNDAscendis Pharma A/S-$1.42-$0.93+$0.49-$0.93$163.17 million$216.28 million8/6/2025Q2 2025ACADACADIA Pharmaceuticals$0.14$0.16+$0.02$0.16$263.07 million$264.57 million8/5/2025Q2 2025BBIOBridgeBio Pharma-$0.83-$0.95-$0.12-$0.95$98.46 million$110.57 million8/5/2025Q2 2025RAREUltragenyx Pharmaceutical-$1.27-$1.17+$0.10-$1.17$161.37 million$166.50 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACADACADIA PharmaceuticalsN/AN/AN/AN/AN/AARWRArrowhead PharmaceuticalsN/AN/AN/AN/AN/AASNDAscendis Pharma A/SN/AN/AN/AN/AN/ABBIOBridgeBio PharmaN/AN/AN/AN/AN/ARAREUltragenyx PharmaceuticalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACADACADIA PharmaceuticalsN/A2.912.83ARWRArrowhead Pharmaceuticals0.394.874.87ASNDAscendis Pharma A/SN/A1.020.69BBIOBridgeBio PharmaN/A5.195.08RAREUltragenyx PharmaceuticalN/A2.452.30Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACADACADIA Pharmaceuticals96.71%ARWRArrowhead Pharmaceuticals62.61%ASNDAscendis Pharma A/SN/ABBIOBridgeBio Pharma99.85%RAREUltragenyx Pharmaceutical97.67%Insider OwnershipCompanyInsider OwnershipACADACADIA Pharmaceuticals26.50%ARWRArrowhead Pharmaceuticals4.30%ASNDAscendis Pharma A/S40.00%BBIOBridgeBio Pharma18.20%RAREUltragenyx Pharmaceutical5.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACADACADIA Pharmaceuticals510168.71 million124.00 millionOptionableARWRArrowhead Pharmaceuticals400138.26 million132.31 millionOptionableASNDAscendis Pharma A/S1,01761.69 million37.02 millionOptionableBBIOBridgeBio Pharma400191.17 million156.38 millionOptionableRAREUltragenyx Pharmaceutical1,29496.37 million91.07 millionOptionableARWR, ACAD, ASND, BBIO, and RARE HeadlinesRecent News About These CompaniesUltragenyx Pharmaceutical Inc. $RARE Stock Holdings Increased by Nordea Investment Management ABOctober 23 at 4:38 AM | marketbeat.comTD Asset Management Inc Reduces Stake in Ultragenyx Pharmaceutical Inc. $RAREOctober 21 at 3:45 AM | marketbeat.comWells Fargo & Company Initiates Coverage on Ultragenyx Pharmaceutical (NASDAQ:RARE)October 20, 2025 | marketbeat.comWedbush Issues Negative Forecast for RARE EarningsOctober 18, 2025 | americanbankingnews.comUltragenyx Pharmaceutical Inc. $RARE Shares Bought by WCM Investment Management LLCOctober 17, 2025 | marketbeat.comResearch Analysts Issue Forecasts for RARE FY2029 EarningsOctober 17, 2025 | americanbankingnews.comUltragenyx: Rough Road Ahead Despite Growing Revenues And CatalystsOctober 16, 2025 | seekingalpha.comWedbush Issues Negative Estimate for RARE EarningsOctober 16, 2025 | marketbeat.comEquities Analysts Set Expectations for RARE FY2029 EarningsOctober 15, 2025 | marketbeat.comHoward Horn Sells 7,942 Shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) StockOctober 15, 2025 | insidertrades.comAberdeen Group plc Raises Stock Holdings in Ultragenyx Pharmaceutical Inc. $RAREOctober 15, 2025 | marketbeat.comVontobel Holding Ltd. Takes Position in Ultragenyx Pharmaceutical Inc. $RAREOctober 15, 2025 | marketbeat.comInsider Selling: Ultragenyx Pharmaceutical (NASDAQ:RARE) CFO Sells 7,942 Shares of StockOctober 14, 2025 | marketbeat.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives Consensus Rating of "Moderate Buy" from BrokeragesOctober 11, 2025 | marketbeat.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Given Consensus Rating of "Moderate Buy" by BrokeragesOctober 11, 2025 | marketbeat.comBank of America Securities Sticks to Its Buy Rating for Ultragenyx Pharmaceutical (RARE)October 10, 2025 | theglobeandmail.comWeiss Ratings Reiterates Sell (E+) Rating for Ultragenyx Pharmaceutical (NASDAQ:RARE)October 9, 2025 | marketbeat.comBank of America Securities Remains Bullish on Ultragenyx Pharmaceutical (RARE)October 8, 2025 | finance.yahoo.comWealth Enhancement Advisory Services LLC Takes $353,000 Position in Ultragenyx Pharmaceutical Inc. $RAREOctober 8, 2025 | marketbeat.comUltragenyx Pharmaceutical (RARE): Valuation Perspectives Following Regulatory Milestones and Pipeline ProgressOctober 3, 2025 | finance.yahoo.comUltragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)October 3, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeARWR, ACAD, ASND, BBIO, and RARE Company DescriptionsACADIA Pharmaceuticals NASDAQ:ACAD$21.82 +0.09 (+0.39%) As of 12:21 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.Arrowhead Pharmaceuticals NASDAQ:ARWR$37.42 +0.08 (+0.20%) As of 12:22 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.Ascendis Pharma A/S NASDAQ:ASND$202.07 +1.06 (+0.53%) As of 12:22 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.BridgeBio Pharma NASDAQ:BBIO$55.30 +1.50 (+2.78%) As of 12:22 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.Ultragenyx Pharmaceutical NASDAQ:RARE$33.59 -0.04 (-0.11%) As of 12:22 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Freeport-McMoRan Posts Strong Earnings Despite Indonesia Shutdown Tesla’s Earnings Review: Does the Juice Justify the Squeeze? Warner Bros. Bidding War Potential: How High Could WBD Shares Go? Boeing Takes Off as FAA Greenlights 737 MAX Production Boost Capital One Just Flashed a Buy Signal—New Highs Could Be Next Why Intuitive Surgical Is a No-Brainer for Long-Term Investors Is Oracle’s AI Rally Over? Wall Street Thinks ORCL Could Hit $400 GM Posts Largest Gain Since the Pandemic: Shares Still Look Cheap Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
